Ibrutinib
Imbruvica · BTKi · BTK (Bruton's tyrosine kinase)
First-generation covalent BTK inhibitor. Binds irreversibly to Cys481 of BTK, blocking B-cell receptor signaling.
Relapsed/refractory MCL; frontline in combination (SHINE)
Michael Wang
Professor, Department of Lymphoma and Myeloma; Director, MCL Program of Excellence · MD Anderson Cancer Center
Peter Martin
Professor of Medicine, Chief of Lymphoma Program · Weill Cornell Medicine
Preetesh Jain
Assistant Professor, Department of Lymphoma and Myeloma · MD Anderson Cancer Center
Simon Rule
Professor of Hematology · University of Plymouth / Derriford Hospital
Ibrutinib Dose Adjustment Does Not Impair Treatment Outcome in Mantle Cell Lymphoma: An Italian Real-Life Multicenter Experience. Results From the REDOT_MCL Study.
Hematological oncology · May 2026
Retrospective analysis of clinical outcomes and risk factors in hematopoietic cell transplantation for relapsed or refractory mantle cell lymphoma in the post-ibrutinib era.
Scientific reports · Apr 2026
Bruton protein-tyrosine kinase (BTK) FDA-approved small molecule inhibitors used for the management of neoplastic and inflammatory disorders.
Pharmacological research · Apr 2026
Zanubrutinib-rituximab followed by shortened chemoimmunotherapy as frontline treatment for mantle cell lymphoma (CHESS): a phase II trial.
Nature communications · Mar 2026
Epidemiology, treatment patterns, and survival outcomes of patients with mantle cell lymphoma in Germany: a retrospective analysis of administrative claims data.
Annals of hematology · Mar 2026
Real-world comparative effectiveness of Bruton tyrosine kinase inhibitors in relapsed/refractory mantle cell lymphoma.
Blood advances · Mar 2026
[Ibrutinib - In combination with immunochemotherapy for intensive first-line treatment of mantle cell lymphoma (MCL)].
Bulletin du cancer · Mar 2026
A Meta-analysis Investigating Response Rates with Continuous Bruton Tyrosine Kinase Inhibitor Monotherapies in the Treatment of B Cell Lymphomas.
Oncology and therapy · Mar 2026
Ibrutinib exposure correlates with improved efficacy of CAR T cells in patients with mantle cell lymphoma.
Blood advances · Feb 2026
Fingertip Fissures Associated with Ibrutinib in an Elderly Patient with Mantle Cell Lymphoma.
Turkish journal of haematology : official journal of Turkish Society of Haematology · Feb 2026
Real-world characteristics, treatment patterns, and outcomes of patients with mantle cell lymphoma by line of therapy.
Future oncology (London, England) · Feb 2026
Cutaneous Adverse Effects in Patients Treated with BTK Inhibitors.
Cancers · Jan 2026
BTK Inhibition in Hematology: From CLL/SLL to Emerging Applications Across B-Cell and Immune Disorders.
Biomolecules · Jan 2026
Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial.
Leukemia · Jan 2026
Lineage-determining transcription factors constrain cohesin to drive multi-enhancer oncogene regulation.
Nature cell biology · Jan 2026
Cardiovascular Safety of Bruton Tyrosine Kinase Inhibitors: From Ibrutinib to Next-Generation Agents.
American journal of cardiovascular drugs : drugs, devices, and other interventions · Jan 2026
Emerging first-line treatment approaches for mantle cell lymphoma.
Leukemia & lymphoma · Jan 2026
SOX11 modulates BCR signaling through the PAX5/CD19 axis for therapeutic targeting in BTK-resistant mantle cell lymphoma.
Blood advances · Dec 2025
Multiple skin tumors in a patient treated with orelabrutinib for mantle-cell lymphoma: Case report.
Medicine · Dec 2025
Acquired MYC rearrangement potentially associated with ibrutinib resistance in mantle cell lymphoma.
Virchows Archiv : an international journal of pathology · Dec 2025